Mr. Green received his MBA from University of London, Cass Business School and his JD from Rutgers University. Mr. Green was General Counsel, Chief Compliance Officer, and Secretary at inVentiv Health until last year, when inVentiv was sold to INC Research in a $7B transaction in which Eric played a pivotal role. Before inVentiv, Mr. Green spent 11 years at Quintiles Transnational Corp. during which time he served as Vice-President & General Counsel of the Commercial division.

According to Dr. Karl B. Thor, CSO of Dignify, “Dignify has a very strong scientific team that has provided strong rationale to support a number of attractive programs for improving the lives of people with neurological disorders such as spinal cord injury. Now that we have this strong scientific foundation, we needed to add someone with experience and expertise on the business side of our company. Eric provides the strategic business development expertise that Dignify requires to move our projects into the clinic. He is a welcome addition to the team”. Dr. Ed Burgard, President of Dignify, added, “It was important for Dignify to find a business person who shares our passion to help resolve the many health burdens that spinal injured individuals and their caregivers must bear. Eric not only provides an executive level of business understanding but is also a person who cares deeply about our mission.”

In reply, Mr. Green stated, “I am very enthusiastic to work with the Dignify team to bring new products to the market. One of the most exciting aspects is that their programs include “first-ever” therapies that target a severe, unmet, medical need; yet they have little or no competition in their therapeutic area.”

About Dignify Therapeutics LLC

Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics’ mission is to provide safe, effective, practical and convenient, pharmaceutical agents to treat bladder and bowel voiding dysfunctions. The Company has been funded by RA Capital Management, Eshelman Ventures, the North Carolina Biotechnology Center, NIDDK, NINDS, NICHD, NIA and the One NC Small Business Program. Dignify, a member of the Blackstone Entrepreneur Network, is located at the First Flight Venture Center in Research Triangle Park, North Carolina.

PRESS CONTACT

Dignify Therapeutics

Ed Burgard

P.O. Box 13169

2 Davis Drive

Research Triangle Park, NC 27709

Phone: 919-371-8138

Email:  eburgard@dignifytherapeutics.com

Website:  https://dignifytherapeutics.com

The post Dignify Therapeutics Announces the Appointment of Eric Green to its Board of Directors appeared first on Dignify Therapeutics.

Dr. Rupniak is an internationally recognized neuroscientist and drug developer, with experience in efficacy and safety pharmacology, toxicology, pharmacokinetics and metabolism, regulatory interactions, and the design of clinical studies. Previously, Dr Rupniak was Vice President of Research and Development at CoLucid Pharmaceuticals, where she played a key role in the development of lasmiditan for migraine. Lasmiditan was acquired by Eli Lilly following CoLucid’s successful IPO. Before this, she was a Distinguished Senior Investigator with Merck, where she supported the development of numerous clinical candidates, including Emend ® for emesis and Vioxx ® for pain. Her main interest is in the identification of important therapeutic uses for novel molecules and differentiating their mechanism of action from established therapies.

“We are delighted to have Dr. Rupniak join Dignify as we progress our programs for bladder and bowel voiding disorders towards the clinic,” said Dr. Karl Thor, Chief Scientific Officer of Dignify Therapeutics.  “Her experience in bringing specific drug classes through the regulatory approval process is immediately applicable for several of our novel programs designed to allow people to regain control of their bladder and bowel function.”

About Dignify Therapeutics LLC

Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics’ mission is to provide safe, effective, practical and convenient,
pharmaceutical agents to treat bladder and bowel voiding dysfunctions. The Company has been
funded by RA Capital Management, Eshelman Ventures, the North Carolina Biotechnology
Center, NIDDK, NINDS, NICHD, NIA and the One NC Small Business Program. Dignify, a member
of the Blackstone Entrepreneur Network, is located at the First Flight Venture Center in
Research Triangle Park, North Carolina.

PRESS CONTACT

Dignify Therapeutics

Ed Burgard

P.O. Box 13169

2 Davis Drive

Research Triangle Park, NC 27709

Phone: 919-371-8138

Email: eburgard@dignifytherapeutics.com

Website: https://dignifytherapeutics.com

The post Dignify Therapeutics announces the appointment of Dr. Nadia Rupniak as Executive Vice President of Drug Development appeared first on Dignify Therapeutics.

Dignify is developing a novel, on-demand, drug-induced voiding therapy for bladder and bowel dysfunction to eliminate or reduce the need for life-long, multiple-daily catheterization of the bladder and manual bowel programs. Worldwide catheter sales total $3 billion/year, while health care expenditures associated with voiding dysfunction cost $7 billion/year in the US alone. Thus, success of Dignify’s lead drug development program will not only improve the quality of life for individuals with voiding dysfunction, it will also substantially reduce health care costs.

“We are very appreciative of our continued support from the NIH” said Chief Scientific Officer, Dr. Karl Thor. “Since 2013 Dignify has also been awarded NIH grant support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke to develop an “on-demand, rapid-onset, short-duration, drug-induced, voiding therapy”.

About Dignify Therapeutics LLC

Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics’ mission is to provide safe, effective, practical and convenient, pharmaceutical agents to treat bladder and bowel voiding dysfunctions, using a repositioning strategy of drug discovery that the team has successfully implemented multiple times over the last 20 years in the fields of urology and gastroenterology. The Company is funded by venture capitalists (RA Capital and Eshelman Ventures), angel investors, the North Carolina Biotechnology Center and the One NC Small Business Program. Dignify, a member of the Blackstone Entrepreneur Network, is located at the First Flight Venture Center in Research Triangle Park, North Carolina.

PRESS CONTACT

Dignify Therapeutics

Ed Burgard

P.O. Box 13169

2 Davis Drive

Research Triangle Park, NC 27709

Phone: 919-371-8138

Email:  eburgard@dignifytherapeutics.com

Website:  https://dignifytherapeutics.com

The post Dignify Therapeutics receives additional $4.1 million in NIH Awards for Bladder and Bowel Therapy appeared first on Dignify Therapeutics.